Table 1. Subject characteristics.
| SJIA flare | SJIA quiescence | polyJIA flare | polyJIA quiescence | control | |
|---|---|---|---|---|---|
| n | 16 | 22 | 11 | 11 | 31 |
| F/M(1) | 6/10 | 8/14 | 10/1 | 9/2 | 10/21 |
| African-American | 1 | 2 | 0 | 0 | 0 |
| Asian | 2 | 2 | 0 | 1 | 4 |
| Caucasian | 9 | 8 | 8 | 5 | 17 |
| Caucasian Hispanic | 4 | 4 | 3 | 3 | 10 |
| >1 Ethnicity | 0 | 1 | 0 | 1 | 0 |
| Mean age (yr) at disease onset ±SD (range) | 7.7±5 (2.6-16.1) | 7.3±5 (1.4-15.7) | 8±4.3 (1.2-14) | 6.4±5 (1-15.1) | N/A |
| Mean age (yr) ±SD at sample collection (range) | 10±4.7 (2.7-18.9) | 11.6±3.8 (5.9-17.6) | 11.9±4.1 (5.1-18) | 12.7±5 (2.6-19.5) | 12±5 (3-18) |
| Fever (%) | 50% | 0 | 0 | 0 | N/A |
| Rash (%) | 52% | 0 | 0 | 0 | N/A |
| Mean Joint Count ±SD (, range) | 6.6±9.3 (0-40) | 0.4±1 (0-4) | 17.4±10.6 (2-36) | 0 | N/A |
| WBC (×103/ul) (mean±SD) | 18.8±10 | 7.2±2.8 | 7.3±1.6 | 6.9±1.1 | ND |
| Platelets (×103/ul) (mean±SD) | 554.5±179 | 324±144 | 447±192 | 302±79 | ND |
| Monocytes (×103/ul) (mean±SD) | 0.7±0.35 | 0.52±0.15 | 0.4±0.1 | 0.52±0.2 | ND |
| Lymphocytes (×103/ul) (mean±SD) | 2.2±1.5 | 2.6±1.9 | 2.4±0.5 | 2.9±0.8 | ND |
| Neutrophils (×103/ul) (mean±SD) | 15.4±9.5 | 4±2.3 | 4±0.9 | 3.3±0.8 | ND |
| Mean Treatment intensity score ±SD (range) | 3.3±1.8(2) (0-6) | 1.6±1.5 (0-5) | 1.9±1 (0-3) | 1.8±1.2 (0-4) | N/A |
| Mean Prednisone dose±SD (mg/kg/day) (range) | 0.5±0.9(2) (0-3) | 0.03±0.09 (0-0.4) | 0.001±0.005 (0-0.02) | 0.006±0.02 (0-0.08) | N/A |
(1)
differences between SJIA and polyJIA are consistent with known epidemiology of JIA [78]
(2)
statistically different from SQ, PF and PQ by ANOVA with Bonferroni correction N/A: not applicable; ND: not done